A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.
Monk BJ, et al. Among authors: aghajanian c.
Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.
Ann Oncol. 2017.
PMID: 28453702
Free PMC article.
Clinical Trial.